leukemia
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
IN8bio to Lay off Nearly Half of Workforce, Narrow Pipeline Focus on AML Cell Therapy
The firm is dropping two glioblastoma programs and cutting 49 percent of its staff to advance its gamma delta T-cell therapy INB-100 in post-transplant AML.
Foundation Medicine, Syndax Pharmaceuticals Partner to Develop CDx for AML Treatment
The companion diagnostic assay, for a drug under development by Syndax, will identify acute myeloid leukemia patients with an NPM1 mutation.
Gilead Optimistic About 11 Percent Q2 Growth in Cell Therapy Sales but Readying for Competition
Premium
The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.
Jul 18, 2024